Dendritic Cells: Location, Function, and Clinical Implications by Castell-Rodríguez, Andrés et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 2
Dendritic Cells: Location, Function, and Clinical
Implications
Andrés Castell-Rodríguez, Gabriela Piñón-Zárate,
Miguel Herrera-Enríquez, Katia Jarquín-Yáñez and
Iliana Medina-Solares
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.68352
Abstract
Dendritic cells (DCs) are antigen-presenting cells derived from bone marrow precur-
sors and form a widely distributed cellular system throughout the body. DCs exert 
immune-surveillance for exogenous and endogenous antigens and the later activa-
tion of naive T lymphocytes giving rise to various immunological responses. Different 
growth  factors and cytokines can modulate the differentiation and function of DCs, 
GM-CSF, M-CSF, Flt3, and TGF-β, resulting in a large variety of DCs with different 
functional abilities. Thus, DCs are classified as plasmacytoid DCs (pDCs), conven-
tional DCs (cDCs), and DCs derived from monocytes (mDCs). Functionally, the cDCs 
may be divided into two states: immature and mature. Immature DCs are specialist in 
uptaking and processing antigens; in contrast, mature DCs are professional in antigen 
presentation. It has been observed that immature cDCs can induce immune tolerance 
while mature cDCs may induce Th2 or Th1 immune responses. It is worth noting that 
different subpopulations of DCs have the ability to secrete different cytokine patterns, 
resulting in the induction of different immunological responses. Furthermore DCs are 
involved in the pathophysiology of several diseases such as contact hypersensitivity, 
autoimmune diseases, or cancer, but they can also be used as therapeutic tools in these 
conditions.
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1. Introduction
Dendritic cells (DCs) are antigen-presenting cells, characterized by a distinctive morphol-
ogy and expression of markers such as CD11c and major histocompatibility complex class II 
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molecules (MHCII). In addition, DCs can recognize pathogens, tissue damage signals, and 
tumor antigens and then migrate to the secondary lymphoid organs where they present anti-
gens and activate T lymphocytes. DCs may induce the development of diverse immunological 
responses, either Th1, Th2, Treg, or Th17. There is a great variety of DCs with different phe-
notypes and localizations that form a cellular system distributed throughout the body and 
that is responsible for immune-surveillance. DCs are classified into conventional DCs (cDCs), 
plasmacytoids (pDCs), and DCs derived from monocytes (mDCs) [1, 2].
DCs are involved in many diseases, for example, contact hypersensitivity and autoimmune 
diseases, so intensive research is underway with the purpose of finding alternatives to induce 
the secretion of tolerogenic cytokines to decrease the activity of DCs in this type of pathologies 
[3, 4]. On the other hand, DCs have an important role in cancer. It has been observed that 
tumor cells may inhibit the maturation of DCs and induce the modification of their pheno-
type to provoke a Th17 or Treg response, which favors the proliferation of tumor cells. In 
addition, DCs are used as a promising alternative in cancer immunotherapy. To date, only 
one DC-based vaccine is available clinically; therefore, the study of immunomodulatory 
 molecules that increase the maturation of DCs for their subsequent use in antitumor immu-
notherapy is underway [4, 5].
In the present chapter, the origin, phenotype of DCs precursors, and the description of the 
subpopulations located in the organism will be reviewed. Also, we analyze the different 
 functional states of DCs and their relationship to the secreted cytokine pattern. Finally, we 
consider the role of DCs in some pathologies.
2. Dendritic cells biology
2.1. Origin and differentiation
2.1.1. Cytokines in DCs differentiation
DCs originate from hematopoietic precursor cells located in the bone marrow. Years ago, it 
was thought that DCs could have a lymphoid or a myeloid origin; then, after some experiments 
realized in 2007, it was found that DCs may originate from the common myeloid progenitor 
(CMP) and from the common lymphoid progenitor (CLP), giving rise to classical or conven-
tional CDs, as well as plasmacytoid CDs [6]. It is important to note that key growth factors are 
needed for DC differentiations, such as Flt3L, granulocyte macrophage colony-stimulating 
factor (GM-CSF), and M-CSF [7] (Figure 1).
Among the different growth factors involved in DCs differentiation, the most important is 
Flt3-L, where the receptor is Flt3 (Fms-like tyrosine kinase 3), a receptor of a protein tyrosine 
kinase located especially in DCs precursor in bone marrow, so it has been proposed that Flt3-L 
is involved in the differentiation of cDCs and pDCs (Figure 1). It has also been suggested that 
Flt3-L/Flt3 regulates the maintenance and development of DCs in lymphoid and mucosal 
organs [8], as Flt3-L is sufficient for the differentiation of pDCs and cDCs from precursor 
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cells with various phenotypes in vitro, and when its expression is forced. In addition, Flt3-L 
deficient mice have shown only 10% of the pDCs and cDCs that are normally located in 
wild type, besides the administration of Flt3-L to those mice restored the levels of pDCs 
and cDCs, while the administration of Flt3-L to wild-type mice increased the levels of 
pDCs and cDCs in spleen [7, 9, 10].
Other important cytokine is granulocyte and macrophage colony-stimulating factor (Figure 1). 
It has been observed that it can induce the differentiation of DCs in vitro and in vivo (Figure 2); 
however, GM-CSF-deficient mice show normal levels of resident DCs of lymphoid organs, 
although there were some alterations in the levels of resident mucous or migratory DCs. So, 
it is believed that GM-CSF is not related to the differentiation of DCs in the steady state, but 
Figure 1. Differentiation of DCs in human and mouse. In human, three DCs precursors are recognized: GMDPs, MDPs, 
and CDPs. As the cells differentiate, they acquire different phenotype. It is accepted that under the influence of Flt3-L, 
cDC1, cDC2, and pDCs originate from CDPs. In mouse, it has been shown that there are several precursors: CMPs, 
MDPs, and CDPs. The latter differentiate into pre-cDCs and pre-pDCs. The pre-cDCs differentiate toward pre-cDC1 
and pre-cDC2 giving rise to the cDC1 and cDC2, respectively. The pre-pDCs differentiate into pDCs. In the figure the 
phenotype of each cell and the cytokines involved in the differentiation process such as cell myeloid progenitors (CMPs), 
macrophages and dendritic cells progenitors (MDPs), common myeloid progenitors (CDPs), granulocytes, macrophages 
and DCs progenitors (GMDPs), pre-conventional dendritic cells (pre-cDCs), pre-plasmacytoid dendritic cells (pre-pDCs), 
pre-conventional dendritic cells 1 (pre-cDC1), pre-conventional dendritic cells 2 (pre-cDC2), conventional dendritic cells 
1 (cDC1), conventional dendritic cells 2 (cDC2), plasmacytoid dendritic cells (pDCs) has been placed.
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in the replenishment of DCs in non-lymphoid organs. In spite of the above, GM-CSF has been 
widely used in the differentiation of DCs in vitro that are subsequently used for therapeutic 
purposes [11, 12].
On the other hand, another cytokine involved in DCs differentiation is macrophage colony-
stimulating factor (Figure 1). M-CSF is involved in DCs differentiation from monocytes and 
is very important for the differentiation of pDCs from certain MCSFR + cell populations in 
bone marrow. Nevertheless, knockout mice for M-CSF and its receptor did not show changes 
in DC levels in lymphoid organs, although there were decreased levels of monocytes and 
Langerhans cells (LCs) [13]. After all, now Flt3-L is considered as the most important cytokine 
in DCs development; nonetheless, M-CSF and GM-CSF are also relevant cytokines in DCs 
development and activation in non-lymphoid tissues [4, 13].
2.1.2. DCs precursors
The differentiation of DCs is carried out from various cell progenitor populations located 
in bone marrow (Figure 1). Multiple experiments have been conducted in order to characterize 
the different populations that can give rise to DCs, macrophages, or lymphocytes. These 
experiments include the isolation of cell populations by flow cytometry and the later treatment 
with Flt3-L, M-CSF, and GM-CSF or cultivated with stromal cells producing these cytokines 
Figure 2. Differentiation of DCs from bone marrow precursors. The figure shows the differentiation of DCs from bone 
marrow precursor. (A) Culture of bone marrow cells at 24 h with GM-CSF. (B) and (C) The culture of bone marrow 
precursor cells after 6 days of culture with GM-CSF. The presence of poorly adherent cells with a great number of long 
and thin extensions is observed. (D) An immature DC MHCII positive is shown after 6 days of culture of bone marrow 
precursor cells with GM-CSF. (E) MHCII expression in DCs, after culturing for 2 h in the presence of LPS, a large increase 
in MHCII expression is observed. (F) A large number of extensions are observed in a DC stained with toluidine blue. 
The arrows point to DCs.
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[8]. As a result, the first cell population with potential to differentiate into DCs, macro-
phages, monocytes, and polymorphonuclear cells was described and named cell myeloid 
progenitor (CMP), characterized by localizing in bone marrow and showing a Lin− c-Kit-high 
Sca1− IL-7Ralpha− phenotype. The CMP differentiation potential was evidenced when poly-
morphonuclear cells, macrophages, and DCs were obtained after CMPs were cultured with 
GM-CSF and Flt-3L-producing stromal cells [14]. Later, CMPs lose their potential to differ-
entiate into granulocytes when initiated with the expression of M-CSFR. These progenitor 
cells are called macrophages and dendritic cell progenitors (MDPs), characterized by the 
phenotype Lin− Sca1− M-CSFR+ Flt3+ c Kit int CX3CR1+. The capacity of differentiation of 
the MDPs was evaluated by in vitro assays, where macrophages and DCs were obtained when 
MDPs were cultivated in the presence of M-CSF or GM-CSF. In vivo assays in irradiated mice 
showed that the inoculation of MDPs was directly involved in the differentiation of DCs and 
macrophages especially in lymphoid organs [13, 14].
Then, MDPs begin to decrease the c-Kit expression, which is indicative of differentiation 
into common dendritic cell progenitors (CDPs), characterized by the expression of the 
phenotype Lin− cKitint, Flt3+ M-CSFR+. CDPs have the ability to differentiate into cDCs 
and pDCs with different phenotypes. So, when CDPs are cultivated in the presence of 
Flt3-L, a cell population CD11c+ MHCII+ is obtained; whereas, when CDPs are treated 
with GM-CSF a different cell population is obtained, since it shows the phenotype CD11c+ 
CD11b+ MHCII+. Also, when CDPs are treated with GM-CSF and Flt3-L cDCs and pDCs 
are acquired. In vivo, the potential of CDPs was evident when their inoculation in irradiated 
mice showed that CDPs were directly involved in the differentiation of CD11c+ CD8+ and 
CD11c+ CD8− cDCs and CD11c+B220+ pDCs. In conclusion, CDPs have the potential to 
differentiate just to pDCs and cDCs [13, 15].
CDPs have the potential to differentiate to Pre-pDCs and Pre-cDCs (pre-cDCs1 and 
 pre-cDCs2). Pre-pDCs are characterized by the low expression of M-CSFR low [1], while 
it has been reported that Pre-cDCs is characterized by the expression of CD11c, Siglec-H, 
SIRPa low, and MHCII int. Pre-cDCs can be differentiated into Pre-cDC1s and Pre-cDC2s 
cells. The Pre-DC1s cells are known by decreasing the expression of M-CSFR, Siglec-H, and 
Ly6c. Ly6c is a monocyte marker. In the case of Pre-cDC2s, they maintain the expression 
of M-CSFR and Ly6c, but decrease the expression of Kit and Siglec-H. It is important to 
mention that Pre-DC1s, Pre-DC2s, and pDCs are located in the periphery, such as blood or 
lymphoid organs, whereas Pre-cDCs, Pre-pDCs, DCP, MDP, and CMP cells are located in 
the bone marrow [10, 16].
On the other hand, the DCs differentiation in human is a little different from its counterpart 
in mice (Figure 1). The cell with potential to differentiate into granulocyte, macrophage, and 
DCs is named granulocytes, macrophages, and DCs progenitor (GMDPs). This population 
is located in the bone marrow and may have the following phenotype: Lin− CD34+ CD38+ 
CD10− CD45RA+ Flt3+ CD123+ M-CSFR-. When these cells initiate the expression of M-CSFR, 
the phenotype changes and they are called macrophages and DCs progenitor, population 
with the capacity of differentiation to macrophages and DCs. Consequently, MDPs increase 
the expression of CD123, so they acquire the ability to differentiate just to DCs (pDCs and 
cDCs), so this cell population is called common DC progenitors (CDPs) [10] (Figure 1).
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2.2. Dendritic cells subsets
2.2.1. Location
There is a great variety of DCs with different phenotypes and location. In general, DCs 
have been divided into conventional, plasmacytoid, and monocyte-derived [1]. The cDCs 
can be divided into cDC1s and cDC2s. The cDC1s are characterized by being CD8+ CD103+ 
in mouse and BDCA3+ (CD141+) in human. CDC2s phenotype is CD11b+ CD4+ CD8− in 
mouse and are BDCA1+ (CD1c+) in human. The plasmacytoid pDCs are positive for B220, 
mPDCA1 and Siglec-h in mice, while in humans they are BDCA4+ and BDCA2+ [17]. 
Another group of DCs derived from monocytes (mDCs) appears only when there is an 
inflammation. Langerhans cells, normal residents of the epidermis and epithelia, are not 
considered on the same lineage of the DCs mentioned above, since they originate from 
precursor cells that migrated to the skin before birth and differentiated into LCs during 
the first week of life [18].
In relation to the origin of the DCs, they all differ from bone marrow progenitor cells that 
have, as their common denominator, the expression of Flt3 and sometimes M-CSFR [19]. 
DCs are more numerous in lymphoid organs and epithelia. In addition, DCs can express 
various molecular markers depending on their location. Thus, pDCs, CD1s, and CD2s can be 
observed in different tissues of the organism [20]. Figure 3 shows to which cluster of cDCs 
each cell belongs. It is necessary to consider the phenotype and particular location of DCs 
in relation to their function on that tissue. For example, the degree of maturation of DCs in 
lymphoid organs is different from that of DCs in other tissues, since DCs are sentinel cells 
responsible for the recognition of pathogens and signals of tissue damage, which induces 
their migration to lymphoid organs to carry out the activation of different subsets of T, natural 
killer (NK), NKT, and B lymphocytes. It has also been studied and analyzed for a long time 
that the inflammatory or tolerogenic microenvironment induced by the cytokines present in 
tissues is essential in the determination of the functions that DCs can have [17].
It is important to know the types of DCs located in the organism, as well as the cytokines 
involved in its activation, so the following explains the different types of DCs located in 
 lymphoid organs, skin, gut, and blood (Figure 4).
2.2.1.1. DCs in lymphoid organs
2.2.1.1.1. Lymph nodes
In the lymph nodes, there are several subsets of DCs, one of them are the CD103+ migratory 
cDCs from peripheral tissues and generally exhibit a mature phenotype characterized by an 
increase in MHCII, CD80, CD86, and CD40. There are also two classes of resident DCs: CD8+, 
CD4+, or CD11b+, which possess an immature phenotype, unless there is an inflammatory 
environment in the lymph node. Also, the presence of CD141+ and CD1a+ DCs, reminiscent 
of the population of cells with the same marker in dermis, has been observed; therefore, these 
cells are considered as migratory [1, 20].
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2.2.1.1.2. Spleen
In the spleen, all DCs are CD8+ and are approximately 20% of the total spleen cells. DCs are 
classified into subsets according to CD11b marker expression. A subset is CD11blow/− DCs and 
shows an immature phenotype (MHCIIlow CD80low/− CD86low/− CD40low/−), proliferates in the 
presence of Flt3L, and expresses molecules such as CD205, CD207, and Clec9a. CD11+ DCs 
subsets are divided into DCs expressing high or low levels of the endothelial cell-specific 
adhesion molecule (ESAM). These two classes of DCs also proliferate in the presence of Flt3L 
and are CD4+ (ESAM) [21].
2.2.1.1.3. Thymus
In the thymus, there are at least three subsets of DCs: CD8+ cDCs (50%), Sirpα+ cDCs 
(20%), and pDCs (30%) [20]. CD8+ cDcS is likely to be derived from specific precursor 
cells. In this regard, studies have been investigated using the reporter of IL-7 receptor, 
Figure 3. Dendritic cells location and phenotype. The cDCs (cDC1 and cDC2) may be located in lymphoid organs, blood, 
and mucous membranes. In lymphoid organs, the cDC1 (CD8+ CD4−) and cDC2 (CD8+ CD4+) are located. In mucoses 
such as respiratory tract and digestive tract, cDC1 (CD103+ CD11b−) and cDC2 (CD103+ CD11b+ or CD103− CD11b+) 
are also found. In blood, the cDC1 are BDCA3+ and the cDC2 express BDCA1+. In skin, the cDC1s are characterized by 
the expression of CD207+ CD103+, and the cDC2 for the expression of CD207− CD11b+.
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which is a  characteristic marker of lymphoid lineage, and of CD207, which is charac-
teristic of CD8+ cDCs, and it has been found that only CD207 was expressed in thymic 
cDCs [22]. Using a new strategy named retroviral barcoding, it was determined that cDCs 
have a great similarity to spleen DCs and progenitors of bone marrow DCs [1]. Unlike 
CD8+ DCs, Sirpα+ DCs and pDCs develop extrathymically and are home to the thymus at 
steady state. Thymic homing of Sirpα+ DCs is dependent on a CCR2-mediated chemotaxis 
while pDC homing is dependent on CCR9 [23]. Both DC subsets are home to the thymus 
through blood vessels, but the specific tissues that originated from have not been compre-
hensively determined.
Figure 4. DCs at different locations. (A) and (B) human skin sections showing epidermal LCs positive for Langerin and 
CD1a, respectively. Arrows in (B) point to basal DCs. In (A), a few Langerin-positive cells (asterisks) are observed in 
the dermis. (C) and (D) Epidermal sheets of mouse skin with LCs positive for MHCII and CD205, respectively. In (E), a 
histological section of spleen showing Fascin-positive DCs is depicted. DCs are located in the T-dependent zone of the 
white pulp. In the thymus (F), a large amount of CD205-positive DCs is observed at the corticomedullary border.
Biology of Myelomonocytic Cells28
2.2.1.2. Blood
Multiple cell lines can be localized in the blood, such as granulocytes, monocytes, and 
lymphocytes, and to study blood DCs, several lineage markers (Lin), such as CD3, CD19, 
CD14, CD20, and CD56, are used to separate populations of DCs by means of flow cytometry 
assays [24]. Thus, populations of cDCs and pDCs can be identified in blood as they are Lin−. 
pDCs are characterized by expressing MHCII, BDCA2, and BDCA4, while the cDCs express 
MHCII and CD11c. Both types of DCs are negative for Lin markers. The cDCs divide into two 
subtypes, BDCA1 (CD1c) or CD141 (BDCA3) cells [25, 26].
2.2.1.3. Skin
In epidermis and dermis, different types of DCs can be found. In the epidermis, LCs con-
stitute 2–4% and are characterized by expressing high concentrations of Langerin (CD207), 
CD45, and low concentrations of CD11c and MHCII. In humans, the expression of CD1a 
has also been observed, but not in mice. Unlike the other DCs, the differentiation of LCs is 
 independent of Flt3; however, they are dependent for their development of Csf-1R, which 
also induces macrophage differentiation, M-CSF, in addition to chemokines CCL2 and CCL20 
[18]. Langerhans cells were considered to be bone marrow dependent; however, it has been 
observed that LCs may have two distinct embryonic origins: the fetal liver and the yolk sac. 
In the mouse dermis, two populations of DCs, the CD103+ and CD8α+, have been observed, 
whose origin is based on the precursor of DCs positive for CLEC9A. It has been observed that 
when these cells are CD24low, CD11blow, and Sirpα+, they are involved in the development of 
Th2 and Th17 responses [27]. In humans, LCs have a  phenotype very similar to that of mice, 
and they may respond to IL-15. On the other hand, in the dermis are several subsets of DCs: 
CD14+ CD1a− DCs, CD14− CD1a+ DCs, and 6-sulpho LacNAc+ DCs [28]. The CD14+ DCs are 
poor activators of CD8+ T cells in contrast to CD14− DCs. The subset CD141+ DCs is extremely 
successful in the activation of CD4+ T lymphocytes. The population of pDCs located in the 
dermis is very low; however, in inflammatory skin diseases such as psoriasis or lupus erythe-
matosus, an increase of this type of skin cells has been observed [29].
2.2.1.4. Gut
DCs in the intestine are located in the lamina propria of the intestinal mucosa, especially in 
the Peyer’s patches of the small intestine. These cells are usually CD103+, CD8+, and CD207+, 
express low concentrations of MHCII, and have been observed to proliferate when there are 
high concentrations of Flt3. There is a second type of DCs that are also located in the lamina 
propria, but which express the markers CD103 and CD11b, although CD103 is expressed in 
low levels. These types of DCs can also be localized in the muscular layer of the digestive 
tract, so they may be confused with CD11b+ macrophages [30].
2.2.2. Cytokine production
As previously mentioned, the DC differentiation is a process occurring in bone marrow. It 
depends on key cytokines (Flt3-L, GM-CSF, and M-CSF) and different cell precursors such 
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as the common myeloid progenitor and the common lymphoid progenitor resulting in the 
obtaining of classical (cDCs) and plasmacytoid DCs (pDCs [17, 18, 31, 32]. As a result of this 
process, different DC populations not only acquire different phenotypes but also colonize 
different tissues and perform different functions [31]. However, when precursors of den-
dritic cells are differentiated in the presence of different factors such as GM-CSF and tumor 
necrosis factor-α (TNF-α), at least two CDs populations give rise, one characterized by the 
expression of CD1a+/E-cadherin+ and another characterized by the expression of CD14+/
CD68+. Both populations shared some characteristics, such as the secretion of some cyto-
kines (IL-1, IL-1, IL-6, IL-7, IL-12, IL-15, IL-18, TNF-, TGF-, M-CSF, and GM-CSF). However, 
when these cells are treated with CD40 ligands, DCs acquire the ability to produce IL-10 
and IL-13 [31].
The progression in the maturation/activation state of the different CDs populations 
involves not only changes in the expression of the receptors present in the cell membrane 
but also their ability to interact with the extra cellular environment and with other cells. 
In this sense, both immature CDs in lymphoid and mucosal tissue and differentiated CDs 
in vitro are characterized by (1) having a weak antigenic presentation capacity, since DCs 
express low levels of MHC-II molecules, and co-stimulatory molecules (CD40, CD80, and 
CD86), where expression increases when DCs are exposed to maturation stimulus such as 
CD40L or IFN-γ; (2) having a high expression of tissue damage receptors such as CD36 and 
Toll-like receptors [26]; (3) having a high expression of molecules involved in the capture 
of antigens of different chemical origin, such as FcγRI, CD1, CD205, CD207, CD209, and 
CLEC-9 [33–37], receptors involved in antigenic internalization and in the release of intra-
cellular signals, promoting greater expression of adhesion molecules [38, 39]; (4) changes 
in the production of cytokines after undergoing the maturation/activation process. Mature 
CDs produce differentially cytokines related to promote the different immune responses 
(Th1, Th2, Th17, and Treg).
In this section, we describe the patterns of cytokine production, produced by the different 
subsets of DCs.
2.2.2.1. Conventional DCs
Human cDCs differentiated from bone marrow precursors in the presence of GM-CSF and 
IL-4 differentially show not only the expression of mRNA but also the production and release 
of different cytokines depending on their maturation stage.
Immature DCs are characterized by having a phenotype CD11c+, CD86−, MHCIlow, MHCIIlow, 
CD40−, CD80low, CD54low, OX40−, and CD8a−, whereas mature DCs are characterized by a phe-
notype CD11c+, CD83+, CD86+, MHCIlow, MHCIIhigh, CD40+, CD80+, CD54+, OX40+, and CD8a−. 
Both immature and mature DCs have different cytokine pattern secretion (Table 1) [17, 32].
It has been observed that the differential expression of cytokines is regulated not only 
according to the type of DCs but also by the activation pathway. lipopolysaccharide (LPS)-
stimulated DCs have been shown to exhibit a positive regulation of IL-1α, IL-1β, and IL-6 and 
to a lesser degree of IL-15, TNF-α, and MIF. On the other hand, when DCs are stimulated with 
Biology of Myelomonocytic Cells30
 anti-CD40 antibodies only discrete changes are observed in the levels of some cytokines, such 
as IL-6, IL-12p40, IL-15, and TNF-α, whereas IL-1α, IL-1β, IL-18, IFN-γ, TGFβ1-3, and MIF 
are not altered. This fact acquires relevance since those DCs that are stimulated via anti-CD40 
may exhibit a phenotype of cDC1s or cDC2s being able to guide the immunological response 
to both TH1 and Th2. By contrast, DCs that are stimulated with LPS show a phenotype of 
cDC1s. This fact is due to a differential signal on the production of IL-23 which strongly inter-
acts with IL-12 [24, 40].
This same pattern of differential activation has been observed in mature murine and canine 
DCs, stimulated with different types of signals, either with endogenous or with exogenous 
stimuli, where regardless of the type of stimulus, mature DCs show a phenotype with an 
Cytokines profile produced by cDCs
Cytokine Immature DCS Mature DCs Activation path of mature DCs
LPS Anti CD40 TNFα
IL1a High Low High Low Low
IL-1β High Low High Low Low
IL-2 Negative Negative Negative – Médium
IL-4 Low Medium Medium – High
IL-6 Low Medium Low Medium Low
IL_d10 Low Medium Medium Medium Medium
IL-12 Low High High High High
IL-12 p35 Negative High High Medium Medium
IL-12 p40 Low High Medium High –
IL-12p70 Low High High High High
IL-13 Low High Low Low High
IL-15 Low High Medium High –
IL-18 Low Medium Low Medium –
IL-23 Low High High Negative –
MIF High High High High –
IFN-γ Low Medium Low – High
TGF-β whole Low Low Negative – Low
TGF-β1 Low Low – – Medium
TGF-β2 Low Low – – –
TGF-β3 Low Low – – –
TNF-α Low High High Medium Medium
Table 1. Cytokines secreted by immature DCs, mature and matured by different pathways.
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increased expression of CD11c, IL-10β, IL-12p40, IL-12β, IL-12β, IL-12β, IL-12β, IL-12β, 
IL-13, and TNF-α, thus contributing to awakening a Th1-type response. In contrast, TNF-α-
stimulated DCs show increased expression of IL-2, IL-4, IL-12p40, IL-13, TNF-α, TGF-β, IFN-
γ, and MCP-2 promoting a Th2 response. This differential production of cytokines appears 
to be due to the involvement of IL-13 that acts similarly to IL-4, thus promoting this response 
Th2 [41, 42] (Table 1).
2.2.2.2. Tolerogenic DCs
Characteristically, some subsets of DCs of myeloid origin that modulate the antigen-specific 
adaptive immune response by presenting auto-peptides to CD4+ T cells in the presence of 
inhibitory signals, anti-inflammatory cytokines, or other molecules that promote regulatory 
T cell populations are also capable of inducing the deletion or clonal anergy of autoreactive 
T cells.
Some mechanisms of the generation of tolerogenic DCs involve stimulation with IL-10, TGF-β, 
IL-6, TNF-α or its combination [43–46], as well as weak stimulation with bacterial products like 
LPS [47], pharmaceutical drugs like dexamethasone [48], and inhibitors of cell signaling such as 
PKCi or CTLA4 [49, 50]. These cells acquire a tolerogenic activity characterized by an immature 
phenotype with weak expression of co-stimulatory molecules, but with a differential production 
of anti- and proinflammatory cytokines.
This production of cytokines by tolerogenic DCs is dependent on the microenvironment in 
which they are found. Thus, the presence of IL-10 promotes a decrease in IL-6, IL-12, and 
IL-23, as well as an increase in the release of TGF-β, PGE
2
, and IL-10, leading to an increase in 
Treg cell populations. In contrast, in the presence of high concentrations of TGF-β, tolerogenic 
DCs show a high expression of the co-inhibitory molecules ILT4, PDL-1, and PDL-2 [51, 52]. 
The synergism of IL-10 and TGF-β promotes similar cytokine production in DCs, but DCs also 
show a high CCR7-dependent migratory capacity with low antigenic activity.
When there is an early exposure to IFN-γ, DCs are guided to a tolerogenic phenotype with a 
reduced endocytic capacity as well as weak expression of IL-12, IL-23, and TNF-α, an effect 
that is maintained even after receiving a second proinflammatory stimulation [53] (Table 2).
2.2.2.3. Plasmacytoid cells
Since their description, pDCs have produced a great controversy about their origin and func-
tion. Unlike other DCs, pDCs generation is controlled by the expression of the transcription 
factor E2-2 [54]. pDCs express CCR9, CD9, CD19, CD123, CD303, and CD304 molecules. They 
also express the BDCA2 receptor, and the histidine transporter Slc15a4, which facilitate the 
signaling of TLRs and the production of IFN and other cytokines [55]. In mice, the pDCs 
express PDCA1 and Siglec-H [56]. In their immature or inactive state, they have a similar 
appearance to plasmatic cells, lacking dendritic cytoplasmic projections, do not show an 
ability for uptake and present antigens and produce large amounts of IFN types I and III. 
However, when these cells are activated, they rapidly undergo a morphological and func-
tional conversion similar to that of cDCs with a capacity to stimulate T cells [2].
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They are known to share with cDCs not only the same progenitor but also the dependence 
of some factors for their differentiation as the cytokine FMS-related tyrosine kinase 3 ligand 
(Flt3L) and interferon-regulating factor 8 (IRF8) [56]. Like other DCs, pDCs are deficient 
of lymphocytic lineage markers. When pDCs are activated by ligands of TLR7 and TLR9, 
they produce high amounts of IFNs types I and III, other cytokines such as IL-6 and IL-12 as 
well as chemokine ligands CCL3, CCL4, CCL5, CXCL9, CXCL10, and CXCL11 [57, 58]. The 
 regulatory capacity of pDCs involves the expression of the indoleamine 2,3-dioxygenase (IDO) 
enzyme [52], a suboptimal presentation of antigens, and the induction of Treg cells [57, 58].
2.3. Processing and antigen presentation
DCs are capable of capturing and processing antigens very efficiently and for this they 
possess  several molecules that have been identified and are discussed below. In general, 
Phenotype and cytokine production by tolerogenic DCs
Mechanism Phenotype Cytokine Tolerance mechanism
IL-10 Low expression of 
costimulatory molecules 
CD11c+, MHCIIlow, CD80low, 
and CD86low
Weak migratory capacity 
CCR7low
Low secretion of IL-6, 
IL-12, and IL-23
High secretion of IL-10, 
PGE2, and TGF-β
Anergy of CD4+ T cells
Induction of Treg cells
TGF-β Low expression of 
costimulatory molecules 
CD11c+ MHCIIlow, CD80low, 
and CD86low
High expression of 
inhibitory molecules 
ILT4high and PD-LI/2high
Low secretion of lI-β, IL-6, 
and IL-12 e IL-23
High secretion of IL-10
Anergy of CD4+ T cells
Induction of Treg cells
Inhibition of the secretion 
of INFγ by CD4+ T cells
IL10 + TGF-β Low expression of 
costimulatory molecules 
CD11c+ MHCHIIlow, 
CD80low, and CD86low
High migratory capacity 
CCR7high
Weak antigenic 
presentation activity
Low secretion of IL-6, 
IL-12, IL-18, and IL-23
High expression of IL-4, 
IL-5, PGE2, and TGF-β
Anergy of CD4+ T cells
Promotion of stimulated 
T-cells-producing IL2low, 
IFN-γlow IL-10high
Dex Low expression of 
costimulatory molecules 
CD11c+, MHCIIlow, CD80low, 
and CD86low
High migratory capacity 
CCR7high and CXCR4high
Low secretion of IL-12, 
IL-23, and TNF-α
High secretion of IL-10
Anergy of CD4+T cells
Induction of Tr1 cells-
producing IL-10
IFN-γ early exposition Low expression of 
costimulatory molecules 
CDIIc+ MHCIIlow, CD80low, 
and CD86low
Weak endocitic capacity
Low secretion of IL-12 Induction of Treg cells 
CD127−/low, CD25high, and 
FoxP3+
Induction of Treg cells 
IL10+, TGF-β+, and FoxP3+
Table 2. Tolerogenic DCs activation pathways with their cytokine secretion profile and phenotype.
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two antigen-processing pathways have been defined, the endocytic pathway and the cytosolic 
pathway, through which exogenous and endogenous antigens are presented, respectively [59].
2.3.1. Exogenous antigens: endocytic way
Exogenous antigens, such as those derived from bacteria, are captured by immature DCs by 
means of endocytosis, phagocytosis, or both, through different molecules such as Fc receptors 
of IgG or lectins such as CD205, which guides their internalization into endocytic compart-
ments with increasing acidity: slightly acidic early endosomes, moderately acidic endoly-
sosomes, and very acidic late endolysosomes [60]. The late endolysosomes are very rich in 
MHCII and it is in these compartments where the antigens are degraded in polypeptides of 
13–18 residues by some acidic proteases such as thiol and aspartyl cathepsins specific for the 
substrate [61, 62]. In these compartments, cathepsin degrades the invariant chain (li) bound 
to MHCII to a 24 amino acid peptide called the class II invariant chain peptide (CLIP), which 
occupies the cleavage of chains α1 and β1 of MHCII. This degradation is regulated by the 
concentrations of cathepsin S and its inhibitor endogenous cystatin C. After the DCs have 
matured, cystatin C decreases and cathepsin S activity is increased, promoting the degrada-
tion of Ii toward CLIP [62, 63]. The cleavage of MHCII where CLIP is placed is the site that can 
occupy the processed antigens and accommodates peptides up to 30 amino acids in size. As 
the CLIP is occupying this cleft, it needs to be removed so that it can be occupied by degraded 
exogenous antigens [61]. This process is induced by human leukocyte antigen (HLA)-DM 
molecules, which structurally resemble MHCII and are not expressed on the cell surface 
of DCs, but act as a peptide exchanger, facilitating the capture of CLIP, leaving the cleft of 
MHC II free to be occupied by the degraded antigenic peptide, resulting in the stabilization 
of MHCII [64]. Finally, the MHCII/processed peptide complex is carried through transport 
vesicles to the plasma membrane where the peptide can be recognized by CD4+ T lymphocytes 
specific for the peptide antigen presented [65]. The overall process is shown in Figure 5.
2.3.2. Endogenous antigens: cytoplasmic way
Presentation of endogenous antigens by MHCI molecules is performed on all nucleated cells 
and involves the degradation of cytosolic proteins and the loading of the resulting peptides 
into newly synthesized MHCI within the rough endoplasmic reticulum [66]. It is worth noting 
that this antigen-processing route also processes viral proteins from infected cells and proteins 
from bacteria that were initially phagocytosed and processed into endosomes but escaped 
from them into the cytoplasm. All these proteins, located in the cytoplasm, are susceptible to 
be degraded by proteasomes [67]. The processing of cytoplasmic proteins begins when they 
are conjugated with several copies of ubiquitin which is recognized by proteasomes. The pro-
teasomes are formed by four protein cylinders, two peripheral α rings, and two β central rings. 
The β rings have catalytic activity located in the β1, β2, and β3 subunits. Proteasomes have a 
broad specificity of protein substrates and can generate a large variety of peptides capable of 
being presented by MHC class I molecules [66, 67]. DCs are highly efficient in the processing 
and presentation of cytosolic proteins because they possess constitutively di-ubiquitin, which 
has a tandem of key functional protein motifs, and proteasomes with a substrate specificity 
that allows peptides resulting from degradation of proteins have a large amount of hydrophobic 
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or basic amino acids, which gives them a high affinity for MHC class I molecules [59, 68]. In 
particular, INF-γ and TNF-α, two proinflammatory cytokines, can induce a rapid increase of 
proteasomes in DCs, along with an increased expression of MHCI [69].
Peptides resulting from protein degradation are transported by an ATP-dependent process 
into the endoplasmic reticulum by a specific antigen-processing (TAP) transporter, which 
consists of two transmembrane proteins called TAP1 and TAP2 [67]. The transported peptides 
may have different lengths, but the transport is optimum for peptides of 8–16 amino acids 
[61]. Note that MHCIs are associated with TAP by means of a small protein called Tapasin, 
which retains MHCI in the endoplasmic reticulum until the peptide has conjugated to them. 
Inside the reticulum, the transported peptide is cut to a length of nine amino acids by a specific 
aminopeptidase in order to fit into the cleavage of MHCI [66]. When this happens, Tapasin 
releases the class I molecules coupled to the peptide antigen that can then be transported to 
the Golgi apparatus and from there to vesicles of transport to the plasma membrane of the 
cells where the antigenic peptides can be presented specifically to CD8+ T lymphocytes [59].
Figure 5. Exogenous antigens processing: endocytic way. Exogenous antigens are captured by immature DCs by 
endocytosis, phagocytosis, or both. Antigens are internalized into endocytic compartments where cathepsin degrades 
the invariant chain (li) bound to MHCII to a class II-invariant chain peptide (CLIP), which occupies the cleavage of 
MHCII. Then, CLIP is removed by HLA-DM molecules and the processed antigens occupy the space. Finally, the 
MHCII/processed peptide complex is carried through transport vesicles to the plasma membrane where the peptide can 
be recognized by CD4+ T lymphocytes.
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2.3.3. Cross-priming
DCs have the ability to capture and process proteins from virally infected cells or tumor cells 
and that, when processed through the endocytic pathway, can be presented not only to CD4+ T 
lymphocytes but also to CD8+ T virgin lymphocytes [60]. This type of presentation is called 
cross-presentation or cross-priming. This process is determined by the nature of the antigens, 
the way they have been captured, and the subsets of DCs performing the presentation [65]. 
Thus, two approaches have been proposed to carry out this type of antigenic presentation. 
The cytosolic pathway involves the transport of antigens from the lumen of endosomes to the 
cytosol where they can be processed by proteasomes until they are coupled to MHCI in 
the endoplasmic reticulum [69]. The vacuolar pathway involves the coupling in endosomes 
of class I molecules to antigenic peptides derived from the degradation of endocytic compart-
ments by lysosomal proteases [70].
3. Dendritic cells: clinical implications
3.1. Delayed contact hypersensitivity
The pathophysiology of contact hypersensitivity consists of two phases: the induction phase 
and the challenge phase. The induction phase begins when the haptens penetrate the stratum 
corneum of the epidermis and are endocytosed by the LCs. LCs are then activated and migrated 
through the lymphatic vessels to the paracortex of regional lymph nodes, where they present 
the haptens in the context of MHCII to CD4+ T lymphocytes [71]. These activated T lympho-
cytes specific for these haptens are expanded clonally and finally reach the circulatory torrent. 
During this process, they express the cutaneous leukocyte antigen (CLA), with which they have 
the possibility to return preferentially to the skin through the high endothelium postcapillary 
veins [72]. The lymphocytes generated in this process are antigen-specific memory lymphocytes 
[73]. This phase lasts in the human between 10 and 15 days and has no clinical repercussions.
The challenge phase begins when haptens, which have already stimulated the induction phase, 
are brought into second contact with the skin. These haptens are endocytosed and presented by 
LCs, keratinocytes, or dermal DCs [74], which can present them to antigen-specific memory T 
lymphocytes located on the skin. Memory T lymphocytes activate CD8+ cytotoxic T lymphocytes 
which are the main effector cells in contact hypersensitivity. These lymphocytes secrete inflam-
matory cytokines and chemokines and induce apoptosis in keratinocytes [75]. Then, intense che-
motaxis of different leukocytes is produced toward the skin resulting in a large inflammatory 
skin reaction [76]. Among the leukocytes that are also attracted are CD4+ Treg lymphocytes that 
modulate the inflammatory response. In humans, this phase occurs at 72 h and persists for a few 
days, after which it rapidly decreases by mechanisms mediated by CD4+Treg lymphocytes [72].
3.2. Autoimmune diseases
Throughout the development, the maturation of the adaptive immune system and dur-
ing the induction of immune responses, B and T lymphocytes show a high rate of genetic 
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recombination in the variable and hypervariable regions of the antigen receptors, so that the 
adaptive immune system has a wide variety of antigen receptors, being able to respond to 
virtually any type of molecule. Because of this phenomenon, there is a high probability that 
different self-antigens are recognized by the immune system, in addition to nonself antigens 
[1, 77]. To prevent the system from reacting against a self-antigen, autoreactive lymphocytes 
must be removed or trained as tolerant cells. Resident reticuloepithelial cells from cortex and 
 marrow of the thymus perform a negative selection process to eliminate such autoreactive 
clones. In this sense, it has been demonstrated that thymic DCs are also actively involved in 
such negative selection processes, and more recently it has been shown that even peripheral 
DCs may migrate to the thymus and participate in this selection [1, 23]. This is highly sig-
nificant as some populations of DCs are directly related to the development of autoimmune 
diseases, which has recently been shown in a study using transgenic mice transfected with 
diphtheria toxin A (DTA) coupled to a resistance cassette to neomycin which were crossed 
with CD11c-Cre mice.
In the progeny, the Cre complex removes the resistance cassette generating toxicity in CD11c+ 
cells, resulting in depletion of DCs including conventional, plasmacytoid, and LCs, which 
led to an increase in the frequency of CD4+ thymocytes and CD4+ lymphocytes in tissues 
together with the spontaneous development of multiorgan autoimmunity [78, 79]. On the 
other hand, the participation of immature DCs in the induction of Treg cells has been docu-
mented, where CD205 receptor stimulation led to a tolerant antigenic presentation, result-
ing in an increase of CD25+ CTLA-4 T cells, via ligands of co-stimulatory molecules such as 
CD28 and CD154, as well as a decrease in IL-2 production and CD4 [79, 80] T proliferation. 
Thus, immature DCs play a crucial role in the activation of Treg, not only to autoantigens but 
also against alloantigens, since it has been observed that the repeated stimulation of CD4+ 
T cells with immature allogeneic DCs in the absence of antigens leads to a differentiation 
toward Tregs cells [81].
On the other hand, it has been evidenced that in a state of non-inflammation (steady state), 
the tolerant response by the immature DCs depends strongly on the control of TGF-β1 [107]. 
LCs and bmDCs upregulate the expression of Axl, which belongs to the family of tyrosine 
kinase receptors, Tyro3, Axl Mer (TAM), which has the function of inhibiting the inflammatory 
response in DCs, in addition to participating in the elimination of apoptotic cells and the 
blockade of proinflammatory cytokine production, which together is essential for the mainte-
nance of self-tolerance [27].
The participation of DCs in autoimmune processes has been controversial, since in dif-
ferent studies the ability of DCs to break tolerance and to induce autoimmune responses 
has been reported, and others have described the ability of DCs to preserve tolerance and 
avoid an autoimmune response. Thus, much of the controversy is due to the functional 
diversity of the different DCs populations, namely that while mature DCs can induce 
strong self-reactive responses, for example, in the central nervous system an amplification 
of experimental autoimmune encephalitis has been observed; it has also been observed 
that the use of immature DCs has the capacity to offer protection against the development 
of autoimmune reactions [81, 82].
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Immature and tolerogenic DCs produce high levels of IL10, IL-2, and TGF-β, which effectively 
promotes the proliferation and activation of inducible regulatory T cells (iTreg), decreasing 
the autoimmune reaction; however, if the tolerance in different models cannot be restored, 
possibly it is due to the activity of CD220+ B cells that potently modulate Th17 responses, 
maintaining the proinflammatory state [79].
The use of DCs as a therapeutic tool in autoimmune reactions has to do not only with their 
ability to produce tolerance-inducing cytokines such as IL-10 and TGF but also with their 
biological capabilities such as the expression of molecules involved in the antigen presentation. 
For example, two populations of IL-10 modulated DCs (IL10DC) having a CD83High, CCR7+, or 
CD83low CCR7-phenotype were recently compared. Assays suppression effector T cells showed 
that iTreg from the CD83High IL-10DCs induced greater suppression than the population of 
iTreg from the CD83low IL-10DCs, and had a higher migratory capacity to lymph nodes, sug-
gesting that they are a good therapeutic candidate [52].
In addition to tolerogenic DCs, other DCs are involved in the modulation of autoimmune 
responses. Thus, other populations of DCs such as plasmacytoids have been evaluated. 
In a model of arthritis induced by methylated bovine serum albumin (mBSA), it is known 
that IFN-α prevents the inflammatory process, pDCs function was assessed in relation 
to TGF-β and IDO. IFN-α was found to increase the expression of IDO1 and the corre-
sponding TGF-β signaling in the pDCs. Likewise, it was also observed that the depletion of 
the pDCs, either during the sensitization phase or already initiated the arthritic response, 
eliminates the protective effect of IFN-α. In addition, this same abrogating effect of IFN-α 
activity was observed when TGF-β signaling was blocked, but exclusively in the signaling 
phase, implying that this IDO1/TGF-β protection pathway is dependent on anti-inflamma-
tory programs, while responses to restimulation are dependent on the participation of the 
pDCs [83].
As previously mentioned, TLR7 and TLR9 play an important role in the biology of pDCs, 
which also involves them in autoimmune responses. In a murine model deficient mice of 
the Gfi1-transcriptional repressor, which modulates myeloid and lymphoid differentia-
tion, show spontaneous autoimmunity like lupus, including high levels of IgM and IgG2a, 
autoantibodies against RNA and DNA, as well as an increased frequency of plasmoblasts 
and germinal centers. In contrast, Gif1 mice do not show this phenotype, but interestingly 
they show an increase in TLR7-dependent DCs activation, where stimulated DCs produce 
increased amounts of TNF-α, IL-6, and IFN-β as well as an increase in phosphorylation of 
the transcription factors NF-κB and IRF7, suggesting the control of the IFN-I-signaling 
pathway, so that apparently the negative regulation of TLR7 in DCs prevents the spontaneous 
development of lupus [81].
3.3. Cancer
Tumor cells have mechanisms to evade the immune system such as the decreased expression 
of class I molecules, the release of tolerogenic cytokines such as TGF-β and IL-10, as well as 
the induction of lymphocyte death. Generally, in the tumor stroma Treg cells, macrophages 
type 2, mast cells, inhibitory myeloid cells, and neutrophils may secrete cytokines that help 
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the growth of the tumor; also, the formation of free radicals may contribute to increase the 
mutation rate in tumor cells [84]. In the stroma, there are also immature DCs that can induce 
the activation of Tregs tumor antigen-specific antigen lymphocytes, which may be involved 
with increased tumor growth [85]. In addition, DCs have been isolated from patients with 
metastases or with advanced stages of the disease and it has been shown that DCs express 
co-inhibitory molecules such as PD-L1, arginase, and IDO, and produce TGF-β, IL-10, and 
prostaglandins E2, resulting in an inhibition of T lymphocytes. It is worth noting that the use 
of immunostimulators can inhibit this suppression effect induced by DCs [86, 87]. In some 
patients, small foci of extratumoral lymphoid tissue known as tertiary lymphoid tissue may 
be localized and in them it is common to find memory T lymphocytes and naive T lympho-
cytes, in addition to mature DCs. When DCs and T lymphocytes have been isolated from this 
tissue, the development of a Th1 response has been observed in addition to the increased 
 survival of patients with cancer. It is important to emphasize that this lymphoid tissue is 
 usually observed in the early stages of the disease.
3.3.1. Antitumoral immunotherapy
DCs can be used in antitumor immunotherapy to induce the development of effective immuno-
logical responses that decrease the size of the tumor mass and increase survival. CD8+ T lym-
phocytes and NK cells, through the release of perforins and granzymes or through the binding of 
FAS/FASL molecules, can induce the death of tumor cells. These lymphocytes may be activated 
by DCs that have presented antigens from a tumor in the lymph nodes closest to the tumor mass. 
Thus, DCs have been differentiated in vitro to be used as a type of adoptive immunotherapy in 
clinical protocols. There are multiple strategies that have been used with DCs as described below.
DCs derived from bone marrow precursor cells and DCs derived from monocytes have been used 
in clinical protocols, with the latter being the most used in immunotherapy against melanoma 
[4, 88]. Cytokines (IL-4, IL-15, and IFN-γ), TLR agonists such as nucleic acids (CpG), Imiquimod, 
LPS, monophosphoryl lipid A, BCG, as well as transfection of DCs with RNA, encoding cyto-
kines, growth factors, and co-stimulatory molecules, have been used to mature DCs [89].
In relation to the antigens used, DCs treated with nucleic acids, whole tumor antigens, tumor 
lysates, and peptides have been used to carry out a specific antitumor response [8]. The clinical 
results have been variable, so DCs-based immunotherapy has been used in combination with 
the administration of antibodies, cytokines, and even radiotherapy and chemotherapy [90].
Regarding melanoma tumor antigens, several have been used to stimulate DCs to elicit 
a specific antitumor immunological response dependent on T CD8 lymphocytes, capable 
on inducing cell tumor death. In this sense, some of the antigens most used for antitumor 
immunotherapy against melanoma are MAGE proteins [91, 92], gp-100 [93], NY-ESO, and 
tyrosinase, among others. Also, in different clinical assays, DCs have been loaded with one 
or more tumor antigens, for example, DCs loaded with various melanoma-specific antigens 
(gp-100 and tyrosinase) were administered in patients with melanoma and had a regression 
success rate of 11% [94], whereas in another clinical study, in which the same antigens were 
used in conjunction with keyhole hemocyanin, 57% of those receiving the therapy showed 
no tumor growth and only 4% showed complete tumor regression [29].
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The success of DCs loaded with proteins or with tumor peptides has been moderate and is 
generally because antigen-specific T lymphocyte proliferation is not high; however, DC-based 
immunotherapy has been more successful than other strategies (e.g., the use of peptide-based 
vaccines) [95]. It should be noted that the low success observed with DCs-based immuno-
therapy is due to the fact that most DCs are applied to patients in stages III and IV of the 
disease by a late detection of cancerous lesions, which are difficult to produce a successful 
immunological response with immunocompetent T lymphocytes [96, 97].
In relation to the delivery of tumor antigens for activating DCs, dead, apoptotic, or necrotic 
tumor cells have been used [5, 98]. DCs can phagocyte tumor cells by means of specific 
 receptors. Thus, apoptotic cells are recognized by the integrin αVβ5, by the CD36 molecule, or 
by means of the phosphatidylserine receptor [99] and necrotic cells are recognized by CD91, 
TLR-2, and TLR4 [99, 100]. One of the advantages of using dead tumor cells is that DCs can 
present antigens by means of MHCI activating CD8+ T lymphocytes by cross-presentation. In 
addition, the haplotype by which the antigens are presented is independent of the response, 
so this type of vaccine can be applied to any patient [3]. These types of vaccines have been 
shown to induce the activation of tumor-specific CD4+ and CD8+ T cells, as demonstrated 
by a study with 13 melanoma patients, where 3 showed tumor regression and 1 showed 
increased IFN levels [101].
Another strategy is the transfection of DCs with tumor RNA or encoding co-stimulatory 
 molecules, cytokines, or growth factors [102]. DCs that have been transfected with RNA 
encoding tumor antigens can present tumor proteins by means of different HLA molecules, 
so that a large number of CD8+ T lymphocyte clones may be activated [103]. Some of the 
melanoma antigens used in this therapy are MAGE, gp-100, MART-1, and p53. The results 
have been moderately satisfactory since the development of an antitumor immune response 
characterized by the presence of CD8+ T lymphocytes and IFN secretion was observed; 
 nonetheless, tumor regression was observed several times. Despite the moderate response, 
this type of vaccine has been shown to not only stimulate the proliferation and activation of 
NK cells but also induce a decrease in Treg cell levels in melanoma patients [104, 105].
Regarding the cytokines or growth factors used to activate or differentiate DCs in antitumor 
immunotherapy treatments, GM-CSF is one of the most widely used, since it can induce differ-
entiation of DCs and monocytes in vivo [104]. On the other hand, RNA encoding for IFN, IL-7, 
and TNF has been transfected into DCs, resulting in cytokine secretion and DCs maturation. 
In some assays, it has also been attempted to transfect cells with RNA encoding cytokines, 
tumor antigens, and co-stimulatory molecules with the aim that with a single  transfection and 
without the need for incubations of 24–48 h with cytokines or tumor  antigens, the cells can 
present antigens and secrete cytokines [106].
4. Conclusions
Several aspects of the biology of DCs have been clarified, however are still missing some 
issues to be resolved.
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1. Nonetheless in mice some precursors have been established for different subpopulations of 
DCs, in humans it is still necessary to clarify precisely which are the immediate  precursors 
of the different subpopulations, in particular of the cDCs.
2. It is necessary to complete the phenotype of subpopulations of DCs in human. It is clear 
that as more molecules are described, in the future this will be a fulfilled task, but at the 
same time, it will make it more difficult to classify the DCs.
3. Protocols of in vitro differentiation of DCs from their precursors must be better defined. 
According to the latest studies, most of the results attributed to DCs are due to cellular 
 heterogeneity, mixtures of DCs, and macrophages. In addition, it is also necessary to 
 consider that there may be a mixture of DCs subpopulations. This issue is very important, 
especially when clinical trials are conducted against tumors or autoimmune diseases.
4. According to their location, DCs have several functions and this is always necessary to keep 
in mind, and more when it comes to understanding the particular immune responses of an 
organ or a tissue. Not all DCs have the same function; they can vary from organ to organ.
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